

**WEST**

Generate Collection

Print

L2: Entry 134 of 135

File: DWPI

Jun 14, 1990

DERWENT-ACC-NO: 1990-209605  
DERWENT-WEEK: 199027  
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Retardation of collagen crosslinking in skin - by treating with compsn.  
including anti-oxidase cpd., e.g. carnosine, anserine, 3-methyl -L-histidine, etc.

INVENTOR: GRIGG, G W; HANNAN, G N

## PATENT-ASSIGNEE:

## ASSIGNEE

COMMONWEALTH SCI & IND RES ORG  
PEPTIDE TECHNOLOGY LTD RES ORG  
PEPTIDE TECH LTDGY LTD RES ORG  
PEPTIDE TECHN LTDY LTD RES ORG

## CODE

CSIR  
PEPTN  
PEPTN  
PEPTN

PRIORITY-DATA: 1988AU-0000675 (September 28, 1988)

## PATENT-FAMILY:

| PUB-NO        | PUB-DATE       | LANGUAGE | PAGES | MAIN-IPC   |
|---------------|----------------|----------|-------|------------|
| WO 9006102 A  | June 14, 1990  |          | 000   |            |
| AU 638681 B   | July 8, 1993   |          | 000   | A61K007/40 |
| AU 8943320 A  | June 26, 1990  |          | 000   |            |
| EP 436611 A   | July 17, 1991  |          | 000   |            |
| EP 436611 A4  | March 11, 1992 |          | 000   |            |
| JP 04502611 W | May 14, 1992   |          | 011   | A61K037/02 |

DESIGNATED-STATES: AU JP US AT BE CH DE FR GB IT LU NL SE DE FR GB IT

CITED-DOCUMENTS:DE 3424781; GB 2143732 ; FR 2609393

## APPLICATION-DATA:

| PUB-NO      | APPL-DATE          | APPL-NO        | DESCRIPTOR |
|-------------|--------------------|----------------|------------|
| AU 638681B  | September 28, 1989 | 1989AU-0043320 |            |
| AU 638681B  |                    | AU 8943320     |            |
| AU 638681B  |                    | WO 9006102     | Based on   |
| EP 436611A  | September 28, 1989 | 1989EP-0910999 |            |
| EP 436611A4 |                    | 1989EP-0910999 |            |
| JP04502611W | September 28, 1989 | 1989JP-0510274 |            |
| JP04502611W | September 28, 1989 | 1989WO-AU00422 |            |
| JP04502611W |                    | WO 9006102     | Based on   |

INT-CL (IPC): A61K 7/00; A61K 7/40; A61K 7/48; A61K 37/02

ABSTRACTED-PUB-NO: WO 9006102A

## BASIC-ABSTRACT:

A method for reducing or preventing collagen crosslinking in skin and/or damage to skin cell DNA is claimed comprising treating the skin with a compsn. comprising an excipient and an active cpd. (I) selected from carnosine, homocarnosine, anserine, 3-methyl-L-histidine, L-alanyl-L-tyrosine, acyl homocarnosine, acetyl carnosine, iodo

carnosine, di-iodo carnosine, anserine nitrate, carbenoxylone carnosine and analogues. The compsn. may also contain a cpd. (II) selected from bilirubin, carotenoids, mannitol, reduced glcathione, selenium, uric acid, vitamin A, vitamin B and vitamin C.

USE/ADVANTAGE - (I) are antioxidant dipeptides which can decrease or prevent collagen crosslinking either during ageing and/or following exposure to UV radiation or sunlight. The method can also prevent DNA damage as a result of UV radiation and can prevent skin cancer. (II) are non-peptide cpds. which can also inhibit or prevent crosslinking of collagen.

CHOSEN-DRAWING: Dwg.0/14

TITLE-TERMS: RETARD COLLAGEN CROSSLINK SKIN TREAT COMPOSITION ANTI OXIDASE COMPOUND  
CARNOSINE ANSERINE METHYL HISTIDINE

DERWENT-CLASS: B05 D21 E19

CPI-CODES: B03-L; B04-A06; B05-B02C; B07-D02; B07-D09; B10-A07; B10-B02D; B10-B02E;  
B10-E04C; B12-A07; B12-M06; D08-B09A; D09-E; E05-K; E06-A01; E10-A07;

CHEMICAL-CODES:

Chemical Indexing M2 \*01\*

Fragmentation Code

F013 F014 F521 H100 H181 H182 H201 J0 J012 J013  
J1 J171 J271 J3 J371 M210 M211 M212 M213 M214  
M215 M216 M220 M221 M222 M231 M232 M233 M262 M273  
M280 M281 M312 M313 M321 M322 M332 M342 M343 M349  
M371 M381 M391 M413 M431 M510 M521 M530 M540 M640  
M782 M903 M904 P943 Q254 Q262

Specific Compounds

08807M 11742M 19176M

Markush Compounds

199027-35401-M

Registry Numbers

1327U 0502U

Chemical Indexing M2 \*02\*

Fragmentation Code

F013 F014 F521 G013 G100 H1 H100 H181 H182 H201  
H401 H441 J0 J011 J012 J1 J171 J371 M210 M211  
M273 M280 M281 M311 M312 M321 M331 M340 M342 M343  
M349 M371 M381 M391 M413 M431 M510 M521 M530 M531  
M540 M782 M903 M904 P943 Q254 Q262

Specific Compounds

11679M 19930M

Registry Numbers

1327U 0502U

Chemical Indexing M2 \*03\*

Fragmentation Code

F012 F013 F014 F015 F019 F421 F422 F499 H7 H715  
H720 H723 J0 J012 J1 J172 J5 J522 L9 L941  
L999 M1 M126 M129 M132 M139 M210 M211 M212 M240  
M283 M311 M312 M322 M323 M332 M342 M343 M372 M392  
M413 M431 M510 M523 M530 M540 M782 M903 M904 M910  
P943 Q254

Specific Compounds

**WEST****End of Result Set**

Generate Collection

Print

L3: Entry 14 of 14

File: DWPI

Oct 2, 1991

DERWENT-ACC-NO: 1991-290177

DERWENT-WEEK: 199744

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Compsn. contg. a di:peptide for dietetic pharmaceutical - is selected from carnosine, homo:carnosine, anserine, homoanserine and ophidine

**Basic Abstract Text:**

USE - Administration of the compsn. to humans or animals has beneficial effects, such as athletic performance improvement in persons subjected to prolonged physical efforts improvement of muscular functional capacity in elderly or weakened subjects and the like and improvement in horse performance in equestrian sports. The pref. dipeptide is carnosine. The compsn. may contain other active ingredients such as carnitine, creatine, amino acids, sugars, mineral salts and vitamins. A suitable dosage of carnosine is in the range 300 mg to 5 g a day. The compsn. suitably takes the form of a powder or granulate distributed in single dose sachets.

**Equivalent Abstract Text:**

The use of the dipeptides selected from the group of carnosine, homocarnosine, anserine, homoanserine, ophidine or physiologically equivalents thereof for the preparation of medicaments for treating muscular fatigue states and for improving athletic performances in persons subjected to prolonged physical efforts.

**Basic Abstract Text (2):**

USE - Administration of the compsn. to humans or animals has beneficial effects, such as athletic performance improvement in persons subjected to prolonged physical efforts improvement of muscular functional capacity in elderly or weakened subjects and the like and improvement in horse performance in equestrian sports. The pref. dipeptide is carnosine. The compsn. may contain other active ingredients such as carnitine, creatine, amino acids, sugars, mineral salts and vitamins. A suitable dosage of carnosine is in the range 300 mg to 5 g a day. The compsn. suitably takes the form of a powder or granulate distributed in single dose sachets.

**Equivalent Abstract Text (1):**

The use of the dipeptides selected from the group of carnosine, homocarnosine, anserine, homoanserine, ophidine or physiologically equivalents thereof for the preparation of medicaments for treating muscular fatigue states and for improving athletic performances in persons subjected to prolonged physical efforts.

**WEST**

Generate Collection

Print

L3: Entry 13 of 14

File: DWPI

Feb 20, 2001

DERWENT-ACC-NO: 2001-260876  
DERWENT-WEEK: 200127  
COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Foodstuff for fatigue recovery, comprises nutrient comprising peptide, and processed component obtained by electrolyzing meat-processing waste liquid and livestock meat extract, under preset pH

## PATENT-ASSIGNEE:

ASSIGNEE

ITO HAM KK

CODE

ITOHN

PRIORITY-DATA: 1999JP-0226008 (August 10, 1999)

## PATENT-FAMILY:

| PUB-NO          | PUB-DATE          | LANGUAGE | PAGES | MAIN-IPC    |
|-----------------|-------------------|----------|-------|-------------|
| JP 2001046021 A | February 20, 2001 |          | 006   | A23L001/305 |

## APPLICATION-DATA:

| PUB-NO        | APPL-DATE       | APPL-NO        | DESCRIPTOR |
|---------------|-----------------|----------------|------------|
| JP2001046021A | August 10, 1999 | 1999JP-0226008 |            |

INT-CL (IPC): A23 J 1/02; A23 L 1/30; A23 L 1/305; A61 K 31/197; A61 K 31/205; A61 K 35/34; A61 K 38/00; A61 P 1/14

ABSTRACTED-PUB-NO: JP2001046021A

## BASIC-ABSTRACT:

NOVELTY - Foodstuff comprises a material/nutrient comprising a water-soluble peptide and a water-soluble component obtained by electrolyzing and concentrating livestock meat-processing waste liquid and livestock meat extract, under acidic or neutral conditions.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a nutrient for fatigue recovery and for reinforcing physical strength. The nutrient contains L-carnitine contained in livestock meat extract, histidine related dipeptide such as carnosine, anserine or balenine, and taurine.

USE - For use as tablet, powder, granule, dispersion or drink, for fatigue recovery and for reinforcing physical strength (claimed).

ADVANTAGE - The foodstuff has high calorie and comprises high energy nutrients and is used as a source of energy. L-carnitine raises blood concentration and accelerates conversion of energy from fats. The concentration of electrolyzed product in acidic or neutral conditions effectively prevents the decomposition of carnitine, histidine-related dipeptide and taurine.

CHOSEN-DRAWING: Dwg.0/2

TITLE-TERMS: FOOD FATIGUE RECOVER COMPRISE NUTRIENT COMPRISE PEPTIDE PROCESS COMPONENT OBTAIN MEAT PROCESS WASTE LIQUID LIVESTOCK MEAT EXTRACT PRESET PH

DERWENT-CLASS: D12 D13

CPI-CODES: D02-A01; D03-F04; D03-F06;